Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04343885
Title In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy (UpFrontPSMA)
Acronym UpFrontPSMA
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Peter MacCallum Cancer Centre, Australia
Indications
Therapies
Age Groups: adult | senior
Covered Countries AUS


No variant requirements are available.